Arrivo BioVentures, LLC
A privately held, venture backed biopharmaceutical development company accelerating biologics and small molecules to improve patient care. Arrivo identifies IND ready/Phase I molecules and advances development through Phase IIb (proof of concept). Arrivo was launched in 2016 with $49M in committed capital.
Ms. Adams has been engaged by Arrivo to provide financial guidance, structure and support from inception through funding activities and asset acquisition.
Emergo Therapeutics, Inc.
Emergo Therapeutics is a privately held, clinical stage biopharmaceutical company developing off patent drugs and related compounds for the treatment of acute inflammatory conditions.
Ms. Adams has been engaged by Emergo to provide financial guidance, operational structure and support as the Company prepares to raise its first funding round.
QuatroBio is the management company for two early-stage drug development companies.
The first, Midnight Pharma LLC, is developing a novel product for the treatment of insomnia and is in Phase 2 and raised $7M in a series A investment. The second, Velo Bio LLC, is developing an orphan drug for the treatment of severe preeclampsia (DIF program) in pregnant women, also in Phase 2. AMAG Pharmaceuticals, Inc. paid $10M for the option to acquire global rights to the DIF program.
QuatroBio was founded by the same management team which founded (and subsequently sold) Aerial BioPharma (JZP-110 asset sale), Neuronex, and Addrenex. All successful drug development companies in the RTP area of North Carolina which Ms. Adams was also associated with in the role of CFO beginning in 2007.
As one of the founders of the QuatroBio, Ms. Adams is continuing as CFO and is responsible for supporting business development and fund raising efforts as well as the internal accounting and financial reporting structure, yearly audits, risk management and human resources as the team advances the drug development programs in Midnight and Velo.
©2018 Copyright Karen J. Adams, All Rights Reserved